汪敏, 双东思, 苏晞. 替格瑞洛与氯吡格雷在ACS并发T2DM行PCI患者中对血小板聚集功能影响的比较[J]. 心脏杂志, 2017, 29(3): 286-289,296. DOI: 10.13191/j.chj.2017.0073
    引用本文: 汪敏, 双东思, 苏晞. 替格瑞洛与氯吡格雷在ACS并发T2DM行PCI患者中对血小板聚集功能影响的比较[J]. 心脏杂志, 2017, 29(3): 286-289,296. DOI: 10.13191/j.chj.2017.0073
    WANG Min, SHUANG Dong-si, SU Xi. Platelet reactivity in patients with acute coronary syndrome and diabetes mellitus undergoing percutaneous coronary intervention and dual antiplatelet therapy with clopidogrel or ticagrelor[J]. Chinese Heart Journal, 2017, 29(3): 286-289,296. DOI: 10.13191/j.chj.2017.0073
    Citation: WANG Min, SHUANG Dong-si, SU Xi. Platelet reactivity in patients with acute coronary syndrome and diabetes mellitus undergoing percutaneous coronary intervention and dual antiplatelet therapy with clopidogrel or ticagrelor[J]. Chinese Heart Journal, 2017, 29(3): 286-289,296. DOI: 10.13191/j.chj.2017.0073

    替格瑞洛与氯吡格雷在ACS并发T2DM行PCI患者中对血小板聚集功能影响的比较

    Platelet reactivity in patients with acute coronary syndrome and diabetes mellitus undergoing percutaneous coronary intervention and dual antiplatelet therapy with clopidogrel or ticagrelor

    • 摘要: 目的 观察急性冠脉综合征(ACS)并发2型糖尿病(T2DM)行经皮腔内冠状动脉介入(PCI)治疗患者中替格瑞洛与氯吡格雷对血小板聚集功能影响的比较。 方法 回顾性的收集2013年3月~2015年3月我院ACS并发T2DM行PCI患者175例,按使用的抗血小板药物分为两组:替格瑞洛组(n=22)和氯吡格雷组(n=153),采用光比浊法分析血小板聚集功能,比较两者血小板聚集功能的差异。 结果 花生四烯酸(AA)诱导的血小板聚集率:氯吡格雷组为(32±20)%,替格瑞洛组为(26±17)%,两组差异无显著性;二磷酸腺苷(ADP)诱导的血小板聚集率:氯吡格雷组为(51±18)%,替格瑞洛组(40±18)%,两组有显著性差异(P=0.01)。 结论 对于ACS并发T2DM行PCI患者,替格瑞洛较氯吡格雷显著减低ADP诱导的血小板聚集率,不影响AA诱导的血小板聚集率。

       

      Abstract: AIM To observe the effect of clopidogrel or ticagrelor on platelet aggregation in patients with acute coronary syndrome(ACS) and type 2 diabetes mellitus(T2DM). METHODS A total of 175 patients with ACS and T2DM in Wuhan Asia Heart Hospital were included in this retrospective study. Patients were divided into two groupsticagrelor group(n=22) and clopidogrel group(n=153). Platelet aggregation function was tested by light transmission platelet aggregation(LTA) and the difference of platelet aggregation function between groups was compared. RESULTS No significant difference was found between groups in arachidonic acid(AA)-induced platelet aggregation rate(32±20)% in clopidogrel group and(26±17)% in ticagrelor group(P=0.160). Adenosine diphosphate(ADP)-induced platelet aggregation rate in ticagrelor group was lower than clopidogrel group(40±18)% vs.(51±18)%, P=0.01. CONCLUSION Ticagrelor significantly decreases ADP-induced platelet aggregation rate moreso than clopidogrel in patients with ACS and T2DM, but no significant difference is found in AA-induced platelet aggregation between drugs.

       

    /

    返回文章
    返回